JP2019535291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535291A5 JP2019535291A5 JP2019528043A JP2019528043A JP2019535291A5 JP 2019535291 A5 JP2019535291 A5 JP 2019535291A5 JP 2019528043 A JP2019528043 A JP 2019528043A JP 2019528043 A JP2019528043 A JP 2019528043A JP 2019535291 A5 JP2019535291 A5 JP 2019535291A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- rna
- introns
- vector according
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 49
- 241001493065 dsRNA viruses Species 0.000 claims description 44
- 241000700605 Viruses Species 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 108020004414 DNA Proteins 0.000 claims description 17
- 108091092195 Intron Proteins 0.000 claims description 17
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 230000002458 infectious effect Effects 0.000 claims description 12
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 101710172711 Structural protein Proteins 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 241000725619 Dengue virus Species 0.000 claims description 6
- 241000710831 Flavivirus Species 0.000 claims description 6
- 241000710772 Yellow fever virus Species 0.000 claims description 6
- 229940051021 yellow-fever virus Drugs 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108091092236 Chimeric RNA Proteins 0.000 claims description 4
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000710886 West Nile virus Species 0.000 claims description 4
- 241000907316 Zika virus Species 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000710801 Rubivirus Species 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021178709A JP2022023198A (ja) | 2016-11-28 | 2021-11-01 | プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426708P | 2016-11-28 | 2016-11-28 | |
| US62/426,708 | 2016-11-28 | ||
| PCT/US2017/062733 WO2018098133A1 (en) | 2016-11-28 | 2017-11-21 | Vaccines against infectious diseases caused by positive stranded rna viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021178709A Division JP2022023198A (ja) | 2016-11-28 | 2021-11-01 | プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535291A JP2019535291A (ja) | 2019-12-12 |
| JP2019535291A5 true JP2019535291A5 (enExample) | 2020-11-12 |
| JP7117015B2 JP7117015B2 (ja) | 2022-08-12 |
Family
ID=62195325
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528043A Active JP7117015B2 (ja) | 2016-11-28 | 2017-11-21 | プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン |
| JP2021178709A Withdrawn JP2022023198A (ja) | 2016-11-28 | 2021-11-01 | プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021178709A Withdrawn JP2022023198A (ja) | 2016-11-28 | 2021-11-01 | プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11058759B2 (enExample) |
| EP (1) | EP3545083A4 (enExample) |
| JP (2) | JP7117015B2 (enExample) |
| KR (1) | KR102511472B1 (enExample) |
| CN (1) | CN110088273B (enExample) |
| MY (1) | MY199945A (enExample) |
| WO (1) | WO2018098133A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024500917A (ja) * | 2020-12-22 | 2024-01-10 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 抗原特異的人工免疫制御性Ｔ（ａｉｒＴ）細胞 |
| CN117321069A (zh) | 2021-03-23 | 2023-12-29 | 百洛克株式会社 | 基于减毒呼肠孤病毒的疫苗组合物及其用途 |
| CN114807232A (zh) * | 2022-05-12 | 2022-07-29 | 中国人民解放军海军军医大学 | 一株西尼罗病毒感染性克隆的构建及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE526411T1 (de) * | 2000-02-16 | 2011-10-15 | Us Gov Health & Human Serv | Avirulente, immunogene flavivirus-chimäre |
| US7455842B2 (en) | 2005-12-05 | 2008-11-25 | University Of Kansas | Chimeric West Nile viruses and uses thereof |
| CN102600481A (zh) * | 2012-03-20 | 2012-07-25 | 中国农业科学院哈尔滨兽医研究所 | 腺病毒/日本脑炎病毒复制子嵌合载体猪瘟疫苗及其应用 |
| US9267114B2 (en) * | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
| CN103088049A (zh) * | 2012-12-26 | 2013-05-08 | 中国人民解放军军事医学科学院生物工程研究所 | 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用 |
| US10369209B2 (en) | 2014-04-11 | 2019-08-06 | Utah State University | Drug target and construct for Japanese encephalitis virus infection |
-
2017
- 2017-11-21 JP JP2019528043A patent/JP7117015B2/ja active Active
- 2017-11-21 CN CN201780073631.8A patent/CN110088273B/zh active Active
- 2017-11-21 EP EP17873411.7A patent/EP3545083A4/en active Pending
- 2017-11-21 KR KR1020197018792A patent/KR102511472B1/ko active Active
- 2017-11-21 US US16/462,383 patent/US11058759B2/en active Active
- 2017-11-21 WO PCT/US2017/062733 patent/WO2018098133A1/en not_active Ceased
- 2017-11-21 MY MYPI2019002595A patent/MY199945A/en unknown
-
2021
- 2021-06-24 US US17/357,368 patent/US20210322535A1/en not_active Abandoned
- 2021-11-01 JP JP2021178709A patent/JP2022023198A/ja not_active Withdrawn
-
2024
- 2024-11-04 US US18/936,799 patent/US20250057932A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Zika virus attenuation by codon pair deoptimization induces sterilizing immunity in mouse models | |
| Sumiyoshi et al. | Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA | |
| ES2327643T3 (es) | Vacunas contra citomegalovirus basadas en alfavirus. | |
| Vander Veen et al. | Alphavirus replicon vaccines | |
| Pugachev et al. | Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection | |
| Lorenzo et al. | Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR−/− mice induced by different DNA vaccination regimens | |
| KR101913790B1 (ko) | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 | |
| CA2432370C (en) | Attenuated flaviviral live vaccine comprising a capsid protein deletion | |
| MY197376A (en) | A rationally oeveloped afrigan swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 tsolate | |
| JP2015535302A (ja) | ビリオン分解に影響を及ぼすフラビウイルスのエンベロープタンパク質変異 | |
| Huang et al. | Vaccine development for mosquito-borne viral diseases | |
| JP2019535291A5 (enExample) | ||
| Pandya et al. | A vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation | |
| Näslund et al. | Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines | |
| Audsley et al. | Virulence determinants between New York 99 and Kunjin strains of West Nile virus | |
| EP3158059B1 (en) | Method for rapid generation of an attenuated rna virus | |
| WO2019220403A3 (en) | Stabilised superoxide dismutase (sod) homolog gene and uses thereof | |
| Dutta et al. | Japanese encephalitis: pathogenesis, prophylactics and therapeutics | |
| Timofeev et al. | Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus | |
| Morris-Downes et al. | A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model | |
| WO2020077395A1 (en) | Virus vaccine | |
| Dehari et al. | RNA-Based Vaccines for Infectious Disease | |
| KR20220016053A (ko) | 키메라 지카-일본 뇌염 바이러스 | |
| Iyer et al. | Complete genome analysis and virulence characteristics of the Louisiana West Nile virus strain LSU–AR01 | |
| WO2007102140A2 (en) | A semliki forest virus replication competent vector with enhanced biosafety |